


 Cite this: *RSC Adv.*, 2023, 13, 4754

 Received 13th January 2023  
 Accepted 20th January 2023

DOI: 10.1039/d3ra00251a

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)



# Synthesis of warfarin analogs: conjugate addition reactions of alkenyl-substituted N-heterocycles with 4-hydroxycoumarin and related substrates†

 Benjamin Goka and Douglas A. Klumpp \*

We have developed a procedure for the Michael addition of 4-hydroxycoumarins to vinyl-substituted N-heterocycles. The chemistry is also suitable for thiocoumarins and quinolinones. A mechanism is proposed involving nucleophilic attack at the vinyl-group of the protonated N-heterocycle.

## Introduction

Warfarin (**1**) is a clinically important anticoagulant drug.<sup>1</sup> It was first approved for use in the mid-1950s and warfarin is currently listed on the World Health Organization's List of Essential Medicines.<sup>2</sup> The substance is commonly prepared using a base-catalyzed reaction of 4-hydroxycoumarin (**2**) with benzalacetone (eqn (1)).<sup>3</sup> Enantioselective addition reactions have also been developed.<sup>4</sup> Our group recently described the Michael addition reactions of 1,3-dicarbonyl compounds with vinyl-substituted N-heterocycles (eqn (2)).<sup>5</sup> Based on this chemistry, we hypothesized that 4-hydroxycoumarins would exhibit similar nucleophilic reactivity with vinyl-substituted N-heterocycles. In the following Communication, we describe a convenient method for the synthesis of heterocycle-containing analogs of warfarin.



## Results and discussion

Using our previous methodology,<sup>5</sup> 4-hydroxycoumarin was reacted with 2-vinylpyridine and acetic acid in acetonitrile and the addition product **3** was isolated in 69% yield (Table 1). The product was exceptionally difficult to purify using chromatography, so a methodology was developed with crystallizing the product directly from the crude product mixture. Similar addition products (**3–8**) were prepared from substituted 4-hydroxycoumarins, including halogen, alkyl, and the methoxy-substituted systems. A modest yield of product **9** was obtained from 5-nitro-2-vinylpyridine and 4-hydroxycoumarin. The conversions were also accomplished with 4-vinylpyridine, providing compounds **10–14** in fair to good yields. The lower yields seem to be associated with systems that did not crystallize well from the crude product mixtures. For example, 4-hydroxycoumarin reacted with di-(4-pyridyl)ethylene but inefficient crystallization provided only a 39% isolated yield of compound **15**. Additionally, we found some systems slowly formed products from double addition reactions. These minor biproducts were identified from mass spectral analysis and NMR analysis of crude product mixtures. The data suggests C- and O-alkylation products (*i.e.* **16**). To suppress formation of these biproducts, some of the conversions were best conducted with equimolar ratios of the vinylpyridine and 4-hydroxycoumarin.


Over the past 50 years, several types of vinyl-substituted heterocycles have been shown to be reactive as Michael acceptors.<sup>6</sup> We have found that 4-hydroxycoumarin also reacts with other types of olefinic heterocycles. When 4-hydroxycoumarin is reacted with a vinyl-substituted 1,2,4-oxadiazole, product **17** is obtained, albeit in low isolated yield (Scheme 1, eqn (3)). Likewise, vinylpyrazine gives the adduct **18** in 39% yield from a reaction with 4-hydroxycoumarin (eqn (4)). The chemistry is also compatible with closely related nucleophiles. Thus, 4-hydroxyquinolin-2(1*H*)-one reacts with 2- and 4-vinylpyridine to give products **19–20** in fair yields (eqn (5) and (6)). Similarly, the brominated 4-hydroxyquinolin-2(1*H*)-one gives compound **21**

Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois, 60115, USA. E-mail: [dklumpp@niu.edu](mailto:dklumpp@niu.edu)

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ra00251a>




**Table 1** Products and yields from the reactions of 4-hydroxy-*ycoumarins* with vinylpyridines



**Scheme 1** Addition reactions with varied heterocycles.

carbon – giving intermediate **23** which rapidly isomerizes to the pyridinium salt of the observed product. Working from the proposed mechanism, we sought to determine if other electrophiles or groups could be transferred to the  $\alpha$ -carbon, besides a simple proton. Compounds **24** were prepared, but unfortunately neither the acetyl or allyl groups were observed to migrate and give products **25**.

from 2-vinylpyridine (eqn (7)). The adduct (**22**) from 4-hydroxy-2*H*-thiopyridin-2-one is also formed in fair yield from 2-vinylpyridine (eqn (8)).



As acid-promoted addition reactions, it is suggested that the acid protonates the N-heterocycle and enhances the electrophilic reactivity of the vinyl group (Scheme 2). We propose a mechanism involving nucleophilic attack of the enol group at the electrophilic vinyl group. As the enol transfers electron density into the vinyl group, negative charge accumulates at the  $\alpha$ -carbon. This leads to a simultaneous proton transfer to the  $\alpha$ -

**Scheme 2** Proposed mechanism for the addition reaction and an unsuccessful application of the chemistry.

## Conclusions

In summary, we have found that 4-hydroxycoumarins react with vinyl-substituted N-heterocycles using an acid promoter. The enol groups of 4-hydroxycoumarins are sufficiently nucleophilic to undergo Michael additions to vinyl-substituted pyridines, pyrazine, and 1,2,4-oxadiazole. Similar reactivity has been demonstrated with 4-hydroxyquinolin-2(1*H*)-one and 4-hydroxy-2*H*-thiochromen-2-one. This work and other recent studies further demonstrates the utility of Michael addition as a useful route to functionalized heterocycles.<sup>7</sup>

## Author contributions

The experimental work was carried out by B. G. and the conceptual work was done by D. A. K.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The support of the NIGMS-NIH (1R15GM126498-01) is gratefully acknowledged. We also acknowledge the generous support from the NSF MRI program (award no. CHE-1726931) for the purchase of a high-resolution mass spectrometer and an NMR instrument (award no. CHE-2117776). We thank Northern Illinois University for the support of the Molecular Analysis Core Facility.

## Notes and references

1 S. S. Garg, J. Gupta, S. Sharma and D. Sahu, *Eur. J. Pharm. Sci.*, 2020, **152**, 105424.

- 2 D. Wardrop and D. Keeling, *Br. J. Haematol.*, 2008, **141**, 757; *World Health Organization Model List of Essential Medicines, 22<sup>nd</sup> List*, 2021, p. 34, <https://www.who.int/publications/item/WHO-MHP-HPS-EML-2021.02>.
- 3 A. M. Rayar, N. Lagarde, F. Martin, F. Blanchard, B. Liagre, C. Ferroud, J.-F. Zagury, M. Montes and M. Sylla-Iyarreta Veitia, *Eur. J. Med. Chem.*, 2018, **146**, 577.
- 4 N. Halland, T. Hansen and K. A. Jorgensen, *Angew. Chem., Int. Ed.*, 2003, **42**, 4955; J. Dong and D.-M. Du, *Org. Biomol. Chem.*, 2012, **10**, 8125; N. M. Moreira, L. S. R. Martelli and A. G. Correa Beil, *J. Org. Chem.*, 2021, **17**, 1952.
- 5 J. C. Hood, Y. Tshikaya, A. R. Manz, M. C. LaPorte and D. A. Klumpp, *J. Org. Chem.*, 2022, **87**, 4908.
- 6 D. A. Klumpp, *Synlett*, 2012, **23**, 1590.
- 7 B. Mao, Z.-W. Chen, J.-F. Wang, C.-H. Zhang, Z.-Q. Du and C.-M. Yu, *Org. Lett.*, 2022, **24**, 6588; W.-D. Chu, Y.-T. Wang, T.-T. Liang, T. Long, J.-Y. Zuo, Z. Shao, B. Chen, C.-Y. He and Q.-Z. Liu, *Org. Lett.*, 2022, **24**, 3965; K. Jung, S. Kim, S. Choi, I. Kim and G. Han, *J. Org. Chem.*, 2021, **86**, 16785; J. Han, J. Kim, J. Lee, Y. Kim and S. Y. Lee, *J. Org. Chem.*, 2020, **85**, 15476; M. Stentzel and D. A. Klumpp, *J. Org. Chem.*, 2020, **85**, 12740; Z. Zhang, S. Dai, L. Li, C. Jia, Y. Zhang and H. Li, *Tetrahedron Lett.*, 2020, **61**, 151926; Y.-L. Zeng, B. Chen, Y. T. Wang, C.-Y. He, Z.-Y. Mu, J.-Y. Du, L. He, W.-D. Chu and Q.-Z. Liu, *Chem. Commun.*, 2020, **56**, 1693; F. Buttard, C. Bertonneau, M.-A. Hiebel, J.-F. Briere and F. Suzenet, *J. Org. Chem.*, 2019, **84**, 3702; R. P. Jumde, F. Lanza, T. Pellegrini and S. R. Harutyunyan, *Nat. Commun.*, 2017, **8**, 1; S. H. Kennedy and D. A. Klumpp, *J. Org. Chem.*, 2017, **82**, 10219; R. P. Jumde, F. Lanza, M. J. Veenstra and S. R. Harutyunyan, *Science*, 2016, **352**, 433; Y.-Y. Wang, K. Kanomata, T. Korenaga and M. Terada, *Angew. Chem., Int. Ed. Engl.*, 2016, **55**, 927; S. Wang, X. Li, H. Liu, L. Xu, J. Zhuang, J. Li, H. Li and W. Wang, *J. Am. Chem. Soc.*, 2015, **137**, 2303.

